| A Phase I Study of SHR-3836 in Patients With Multiple Myeloma (NCT07490613) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2026-06-02 |
| HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors (NCT07296341) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2026-01-08 |
| A Study of Single and Multiple Doses of HRS-6257 in Healthy Subjects (NCT07301333) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2025-12-30 |
| A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors (NCT07268040) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2025-12-23 |
| A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors (NCT07229586) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2025-12-02 |
| A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer (NCT07229729) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2025-11-24 |
| Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors (NCT07073534) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2025-07-24 |
| A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors (NCT06895928) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2025-03-28 |
| A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma (NCT06738251) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2025-02-12 |
| A Mass Balance Study of [14C] SHR6508 in Chinese Hemodialysis Subjects With Secondary Hyperparathyroidism (NCT06877247) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2024-12-23 |
| A Phase II Study of SHR-4602 as Montherapy or in Combination With Other Anti-tumor Therapies in Advanced Solid Tumors (NCT06704828) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2024-12-01 |
| SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (NCT06649292) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2024-11-22 |
| A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy (NCT06654440) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2024-11-15 |
| A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma (NCT06639347) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2024-11-04 |
| A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors (NCT06605222) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2024-10-04 |
| A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NCT06589778) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2024-09-27 |
| Phase Ⅱ Study of Adductor Canal Block With HR18034 for Postsurgical Pain Management in TKA (NCT06509958) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2024-08-20 |
| A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer (NCT06512051) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2024-07-30 |
| A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors (NCT06474455) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2024-07-02 |
| A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer (NCT06474468) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2024-06-20 |
| The Trial of SHR6508 in Secondary Hyperparathyroidism (NCT06434961) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2024-06-14 |
| Phase Ib/II Study of HRS2398 in Combination With Adebrelimab in Patients With Advanced Solid Tumors (NCT06439589) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2024-06-12 |
| SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor (NCT06350006) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2024-05-29 |
| A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors (NCT06417554) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2024-05-13 |
| Investigating the Safety and Efficacy of SHR6508 Injection in the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients : A Multicenter, Long-term Clinical Trial (NCT06236295) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2024-02-20 |
| Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients (NCT06199037) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2024-02-05 |
| A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC) (NCT06108492) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2023-11-28 |
| A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma (NCT06104553) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2023-11-17 |
| A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis (NCT06012812) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2023-09-06 |
| The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors (NCT05836948) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2023-05-18 |
| A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors (NCT05794477) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2023-04-28 |
| Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors (NCT05701709) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2023-04-06 |
| A Study of HR18034 for Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy (NCT05769855) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2023-03-21 |
| A Trial of SHR-7367 in Subjects With Advanced Solid Tumors (NCT05740202) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2023-03-06 |
| A Phase 1 Study of SHR-A2102 in Subjects With Advanced Solid Tumors. (NCT05735275) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2023-03-03 |
| A Study of SHR6508 in Secondary Hyperparathyroidism (NCT05663411) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2023-02-24 |
| Phase Ⅱ Study of Intercostal Nerve Block With HR18034 for Postsurgical Pain Management (NCT05744674) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2023-02-21 |
| A Study of SHR-1707 With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease (NCT05681819) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2023-02-17 |
| A Trial of SHR-1905 in Subjects With Severe Uncontrolled Asthma (NCT05593250) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2023-01-17 |
| A Study of SHR-1501 Alone or in Combination With BCG or SHR-1316 in Subjects With NMIBC (NCT05410730) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2022-11-23 |
| Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis (NCT05549947) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2022-10-08 |
| A Study of HR19024 in Subjects With Advanced Solid Tumor (NCT05463432) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2022-08-10 |
| A Trial of HR18034 for Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy. (NCT05376904) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2022-06-13 |
| A Trial of SHR6508 in Secondary Hyperparathyroidism (NCT05221008) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2022-03-10 |
| Clinical Study on the Efficacy and Safety of Multiple Oral Administrations of SHR2285 Tablets in Patients Undergoing Elective Total Knee Arthroplasty (NCT05203705) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2022-03-07 |
| A Study of SHR-A1909 in Subjects With Advanced Malignant Tumors (NCT05162469) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2022-02-23 |
| A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE SUBCUTANEOUS INJECTIONS OF SHR-1819 IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (NCT05197023) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2022-01-01 |
| A Study of HRS2543 in Patients With Advanced Tumors (NCT05068856) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2021-12-28 |
| A Study of SHR-A1912 for Injection in Patients With B Cell Lymphomas (NCT05113069) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2021-12-22 |
| A First-in-human Study of HRS2398 Tablets in Subjects With Advanced Malignant Tumors (NCT05144061) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2021-12-20 |
| A Trial of Dexmedetomidine Hydrochloride Nasal Spray in Preoperative Sedation of Children (NCT05111431) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2021-11-24 |
| A Phase 1 Study of HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer (NCT04993430) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2021-10-26 |
| A Trial of SHR-A1904 in Patients With Advanced Pancreatic Cancer (NCT04928625) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2021-08-06 |
| A Study of SHR-A1904 in Patients With Advanced Solid Cancer (NCT04877717) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2021-07-01 |
| A Study of SHR-1707 in Healthy Young Adult and Elderly Subjects (NCT04973189) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2021-05-08 |
| A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Escalation Study in Healthy Subjects (NCT04772365) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2021-03-01 |